

Tae Min Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/548228/publications.pdf>

Version: 2024-02-01

261
papers

11,185
citations

50276

46
h-index

38395

95
g-index

267
all docs

267
docs citations

267
times ranked

15901
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 984-993.	10.7	689
2	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology</i> , The, 2019, 20, 1083-1097.	10.7	611
3	Capmatinib in <i>MET</i> Exon 14 Mutated or <i>MET</i> -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	27.0	542
4	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
5	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 874-886.	10.7	453
6	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.	1.6	355
7	Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 642-650.	10.7	352
8	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 3065-3074.	1.6	349
9	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 538-547.	1.6	221
10	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	7.0	217
11	Mechanisms of Acquired Resistance to AZD9291. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1736-1744.	1.1	202
12	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIIE extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2005, 106, 3785-3790.	1.4	165
13	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , The, 2022, 23, 53-64.	10.7	165
14	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	7.1	160
15	Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. <i>Cell</i> , 2019, 177, 1842-1857.e21.	28.9	153
16	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. <i>Modern Pathology</i> , 2015, 28, 1154-1166.	5.5	143
17	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	4.1	136
18	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1430.	7.4	136

#	ARTICLE	IF	CITATIONS
19	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , 2016, 68, 1079-1089.	2.9	135
20	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 459-470.	4.2	132
21	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 215-224.	3.4	128
22	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	1.8	125
23	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 α and STAT3. <i>Oncotarget</i> , 2016, 5, e1108514.	4.6	124
24	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	1.1	119
25	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2379-2387.	7.0	116
26	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	12.8	115
27	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 263-270.e2.	2.6	107
28	Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	1.6	107
29	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 15035-15049.	1.8	94
30	Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. <i>Journal of Neuro-Oncology</i> , 2015, 121, 141-150.	2.9	92
31	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 891-902.	10.7	92
32	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2022, 17, 103-115.	1.1	89
33	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
34	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	4.1	75
35	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 581-590.	2.8	71
36	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015, 20, 1312-1319.	3.7	70

#	ARTICLE	IF	CITATIONS
37	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	1.8	69
38	Extranodal NK/ST cell lymphoma, nasal type: New staging system and treatment strategies. <i>Cancer Science</i> , 2009, 100, 2242-2248.	3.9	68
39	Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 980.	2.5	67
40	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	2.6	66
41	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 463-474.	3.6	64
42	Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. <i>European Radiology</i> , 2018, 28, 4350-4361.	4.5	63
43	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	4.1	56
44	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	4.5	55
45	Injury-Mediated Vascular Regeneration Requires Endothelial ER71/ETV2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 86-96.	2.4	54
46	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. <i>Scientific Reports</i> , 2021, 11, 19712.	3.3	54
47	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 555-563.	3.0	49
48	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	3.0	49
49	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. <i>Cancer Science</i> , 2010, 101, 1199-1203.	3.9	48
50	Cancer Patients' Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea. <i>Cancers</i> , 2021, 13, 3883.	3.7	48
51	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. <i>Cancer Research and Treatment</i> , 2019, 51, 951-962.	3.0	48
52	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 331-338.e4.	2.6	47
53	Intratatumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , 2018, 13, e0189766.	2.5	46
54	Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4504.	1.6	45

#	ARTICLE	IF	CITATIONS
55	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
56	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2015, 90, 381-387.	2.0	44
57	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 907-916.	3.0	44
58	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>American Journal of Pathology</i> , 2017, 187, 980-986.	3.8	44
59	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 25.	17.0	41
60	Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. <i>Cancer Research and Treatment</i> , 2017, 49, 387-398.	3.0	41
61	Ceritinib in patients with advanced anaplastic lymphoma kinase-“rearranged anaplastic large-cell lymphoma. <i>Blood</i> , 2015, 126, 1257-1258.	1.4	40
62	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. <i>Theranostics</i> , 2020, 10, 10838-10848.	10.0	39
63	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. <i>Supportive Care in Cancer</i> , 2013, 21, 183-190.	2.2	38
64	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 570-578.	1.7	38
65	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 122-128.	2.0	38
66	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. <i>Oncologist</i> , 2019, 24, e740-e748.	3.7	38
67	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. <i>BMC Cancer</i> , 2016, 16, 363.	2.6	37
68	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	1.4	37
69	Updated survival of patients (pts) with previously treated <i>BRAF</i> V600E“mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. <i>Journal of Clinical Oncology</i> , 2017, 35, 9075-9075.	1.6	37
70	Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 321-328.	2.9	34
71	Magnetic Nanowire Networks for Dual-Isolation and Detection of Tumor-Associated Circulating Biomarkers. <i>Theranostics</i> , 2018, 8, 505-517.	10.0	33
72	Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus l-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). <i>Annals of Hematology</i> , 2015, 94, 437-444.	1.8	32

#	ARTICLE	IF	CITATIONS
73	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020, 71, 422-425.	5.8	32
74	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 670-675.	3.0	32
75	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 116.	2.6	31
76	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 736-744.	1.9	31
77	Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 40.	1.7	31
78	Predictors of survival for patients with cancer after cryptogenic stroke. <i>Journal of Neuro-Oncology</i> , 2016, 128, 277-284.	2.9	30
79	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. <i>BMC Cancer</i> , 2016, 16, 170.	2.6	30
80	Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 53-63.	1.3	29
81	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2019, 24, 20.	3.7	29
82	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. <i>Anticancer Research</i> , 2015, 35, 175-82.	1.1	29
83	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1556-1566.	1.1	28
84	Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. <i>European Radiology</i> , 2017, 27, 1176-1185.	4.5	27
85	Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. <i>European Radiology</i> , 2017, 27, 3156-3166.	4.5	27
86	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017, 49, 44-53.	3.0	27
87	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 193-203.	3.0	26
88	Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8006-8006.	1.6	26
89	A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11078-11078.	1.6	26
90	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1140-1149.	1.7	26

#	ARTICLE	IF	CITATIONS
91	Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1387-1396.	4.1	25
92	Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3057-3057.	1.6	24
93	Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9505-9505.	1.6	24
94	Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9014-9014.	1.6	23
95	Primary Prophylaxis for <i>Pneumocystis jirovecii</i> Pneumonia in Patients Receiving Rituximab. <i>Chest</i> , 2022, 161, 1201-1210.	0.8	23
96	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 91-98.	0.8	22
97	Radiomics-based neural network predicts recurrence patterns in glioblastoma using dynamic susceptibility contrast-enhanced MRI. <i>Scientific Reports</i> , 2021, 11, 9974.	3.3	22
98	Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9515-9515.	1.6	22
99	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8389.	3.3	22
100	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 520-528.	1.1	21
101	Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI. <i>Korean Journal of Radiology</i> , 2021, 22, 1514.	3.4	21
102	Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9003-9003.	1.6	21
103	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 514-522.	1.7	21
104	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2014, 46, 323-330.	3.0	21
105	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. <i>Cancer Research and Treatment</i> , 2015, 47, 630-637.	3.0	21
106	Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. <i>Laboratory Investigation</i> , 2022, 102, 160-171.	3.7	21
107	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. <i>Oncologist</i> , 2015, 20, 1119-1120.	3.7	20
108	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , 2016, 17, 245-252.e1.	2.6	20

#	ARTICLE	IF	CITATIONS
109	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-“Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. <i>Clinical Lung Cancer</i> , 2017, 18, e169-e178.	2.6	20
110	Differentiation of High-Grade from Low-Grade Astrocytoma: Improvement in Diagnostic Accuracy and Reliability of Pharmacokinetic Parameters from DCE MR Imaging by Using Arterial Input Functions Obtained from DSC MR Imaging. <i>Radiology</i> , 2018, 286, 981-991.	7.3	20
111	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1231-1240.	3.0	20
112	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 1112-1119.	0.4	19
113	Korean Cancer Patients’s™ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	3.0	19
114	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 88-97.	3.0	19
115	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 16, 425-433.	1.7	18
116	Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. <i>Blood</i> , 2018, 132, 1683-1683.	1.4	18
117	ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 13-14.	1.4	18
118	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. <i>Lung Cancer</i> , 2014, 86, 363-368.	2.0	17
119	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 873-883.	2.5	17
120	The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1186-1193.	3.0	17
121	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	3.3	17
122	Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. <i>Blood</i> , 2020, 136, 17-19.	1.4	17
123	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2006-2006.	1.6	17
124	A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. <i>Oncologist</i> , 2014, 19, 1129-1130.	3.7	16
125	Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging. <i>Korean Journal of Radiology</i> , 2015, 16, 1341.	3.4	16
126	Preclinical development of a humanized neutralizing antibody targeting HGF. <i>Experimental and Molecular Medicine</i> , 2017, 49, e309-e309.	7.7	16

#	ARTICLE	IF	CITATIONS
127	Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments. <i>Molecular Neurobiology</i> , 2018, 55, 4918-4926.	4.0	16
128	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG16-07. <i>Thoracic Cancer</i> , 2020, 11, 3482-3489.	1.9	16
129	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR T790M-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1859-1871.	1.1	16
130	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	1.6	16
131	Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2020, 56, 559-567.	3.3	16
132	Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging. <i>PLoS ONE</i> , 2014, 9, e113587.	2.5	15
133	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Leukemia and Lymphoma</i> , 2016, 57, 1956-1960.	1.3	15
134	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. <i>Cytotherapy</i> , 2019, 21, 603-611.	0.7	15
135	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e442-e451.	2.6	15
136	A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1953-1953.	1.4	15
137	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). <i>Journal of Clinical Oncology</i> , 2018, 36, 2513-2513.	1.6	15
138	Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients. <i>Oncotarget</i> , 2017, 8, 20340-20353.	1.8	15
139	Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. <i>Radiation Oncology Journal</i> , 2020, 38, 35-43.	1.5	15
140	Early cognitive function tests predict early progression in glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 137-143.	1.6	14
141	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
142	Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	4.1	14
143	Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> . 2020. 477. 131-142.	2.8	14
144	Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma. <i>Cancer Research and Treatment</i> , 2021, 53, 389-398.	3.0	14

#	ARTICLE	IF	CITATIONS
145	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 720-728.	3.0	14
146	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	1.3	13
147	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 175-181.	1.7	13
148	CD21-independent Epstein-Barr virus entry into NK cells. <i>Cellular Immunology</i> , 2018, 327, 21-25.	3.0	12
149	Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. <i>Thrombosis Research</i> , 2019, 183, 131-135.	1.7	12
150	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 699-711.	2.8	12
151	Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI. <i>European Radiology</i> , 2021, 31, 9098-9109.	4.5	12
152	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2069-2069.	1.6	12
153	Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9593-9593.	1.6	12
154	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1313-1323.	1.7	12
155	Role of radiation therapy in primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 629-638.	2.9	11
156	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With <i>BRAF</i> ^{V600} Mutationâ€“Positive Metastatic Malignancy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1067-1073.	2.0	11
157	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 135, 31-38.	2.8	11
158	Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value. <i>American Journal of Neuroradiology</i> , 2020, 41, 49-56.	2.4	11
159	A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3007-3007.	1.6	11
160	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019, 134, 1568-1568.	1.4	11
161	Application of diffusion-weighted imaging and dynamic susceptibility contrast perfusion-weighted imaging for ganglioglioma in adults: Comparison study with oligodendroglioma. <i>Journal of Neuroradiology</i> , 2016, 43, 331-338.	1.1	10
162	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	1.4	10

#	ARTICLE	IF	CITATIONS
163	Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- β 2 and PD-L1. <i>Journal of Clinical Oncology</i> , 2018, 36, 9017-9017.	1.6	10
164	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
165	Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 940-943.	1.3	9
166	Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. <i>Neuroradiology</i> , 2015, 57, 1111-1120.	2.2	9
167	MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. <i>PLoS ONE</i> , 2016, 11, e0166096.	2.5	9
168	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. <i>Cancer Research and Treatment</i> , 2016, 48, 304-311.	3.0	9
169	Comparison of Native <i>Escherichia coli</i> L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Cancer Research and Treatment</i> , 2018, 50, 670-680.	3.0	9
170	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase α -positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	1.9	9
171	Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling. <i>Neuro-Oncology</i> , 2021, 23, 837-847.	1.2	9
172	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. <i>Haematologica</i> , 2021, 106, 2277-2280.	3.5	9
173	A Phase 2 Study of Odronektamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 28-29.	1.4	9
174	MR Imaging Evaluation of Intracerebral Hemorrhages and T2 Hyperintense White Matter Lesions Appearing after Radiation Therapy in Adult Patients with Primary Brain Tumors. <i>PLoS ONE</i> , 2015, 10, e0136795.	2.5	9
175	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 885-893.	1.7	9
176	Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). <i>Cancer Research and Treatment</i> , 2020, 52, 505-515.	3.0	9
177	Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open-label phase 2 study. <i>Cancer Medicine</i> , 2022, 11, 371-379.	2.8	9
178	Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). <i>Journal of Clinical Oncology</i> , 2022, 40, 9039-9039.	1.6	9
179	Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. <i>Leukemia and Lymphoma</i> , 2017, 58, 2624-2632.	1.3	8
180	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. <i>Cancer Letters</i> , 2020, 495, 135-144.	7.2	8

#	ARTICLE	IF	CITATIONS
181	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2020, 38, 1472-1482.	2.6	8
182	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1605-1617.	4.2	8
183	Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae. <i>Cancer Research and Treatment</i> , 2021, 53, 983-990.	3.0	8
184	Tumor <i>LAG3</i> and <i>NY-ESO1</i> expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 619-630.	1.9	8
185	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0133371.	2.5	7
186	Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. <i>Scientific Reports</i> , 2018, 8, 456.	3.3	7
187	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 202.	2.2	7
188	Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI. <i>European Radiology</i> , 2020, 30, 2171-2181.	4.5	7
189	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 8575-8575.	1.6	7
190	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β^2 and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9558-9558.	1.6	7
191	Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01. <i>Cancer Research and Treatment</i> , 2018, 50, 590-598.	3.0	7
192	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: A retrospective cohort study. <i>Lung Cancer</i> , 2014, 85, 320-325.	2.0	6
193	Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas. <i>Korean Journal of Radiology</i> , 2021, 22, 233.	3.4	6
194	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 3076-3076.	1.6	6
195	Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 7534-7534.	1.6	6
196	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1116-1124.	1.7	6
197	A phase 1/2 study of BLU-945 in patients with common activating <i>EGFR</i> -mutant non-small cell lung cancer (NSCLC): SYMPHONY trial in progress. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9156-TPS9156.	1.6	6
198	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575.	4.5	5

#	ARTICLE	IF	CITATIONS
199	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)., 2021, , .		5
200	Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. Journal of Clinical Oncology, 2015, 33, 4554-4554.	1.6	5
201	An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated <i>BRAF</i> V600E mutant advanced non-small cell lung cancer (NSCLC;) Tj ETQq1 1 0.784314 rgt /Overlock 10 T	1.7	5
202	Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer. Korean Journal of Internal Medicine, 2021, 36, 975-984.	1.7	5
203	A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, TPS9142-TPS9142.	1.6	5
204	Histologically diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report. Journal of Dermatology, 2019, 46, e464-e466.	1.2	4
205	Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in high-risk human papillomavirus cervical carcinomas. Cancer Medicine, 2020, 9, 8243-8257.	2.8	4
206	Hydroa vacciniforme-like lymphoproliferative disorder in Korea. Scientific Reports, 2020, 10, 19294.	3.3	4
207	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. Cancer Immunology, Immunotherapy, 2021, 70, 1755-1769.	4.2	4
208	Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. Cancer Research and Treatment, 2021, 53, 1195-1203.	3.0	4
209	Risk Stratification to Define the Role of Radiotherapy for Benign and Atypical Meningioma: A Recursive Partitioning Analysis. Neurosurgery, 2022, 90, 619-626.	1.1	4
210	Recursive partitioning analysis for disease progression in adult intracranial ependymoma patients. Journal of Clinical Neuroscience, 2017, 46, 72-78.	1.5	3
211	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3113-3113.	1.6	3
212	First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ) Tj ETQq0 0 QrgBT /Overlock 10 T	1.6	3
213	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 182-188.	3.0	3
214	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. Cancer Research and Treatment, 2019, 51, 169-177.	3.0	3
215	<i>ALK</i> Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights. Archives of Pathology and Laboratory Medicine, 2022, 146, 1460-1470.	2.5	3
216	Effects of percutaneous injection laryngoplasty on voice and swallowing problems in <sc>cancer-related</sc> unilateral vocal cord paralysis. Laryngoscope Investigative Otolaryngology, 2021, 6, 800-806.	1.5	2

#	ARTICLE	IF	CITATIONS
217	Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). <i>Cancer Research and Treatment</i> , 2022, 54, 396-405.	3.0	2
218	Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3972-3972.	1.4	2
219	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9636-TPS9636.	1.6	2
220	Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, e1-e6.	2.6	1
221	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 145-150.	1.5	1
222	Epstein-Barr Virus-Associated Vesiculopapular Eruption on the Face of a Patient with Natural Killer T Cell Lymphoma. <i>Annals of Dermatology</i> , 2017, 29, 618.	0.9	1
223	Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions. <i>American Journal of Neuroradiology</i> , 2019, 40, 2052-2058.	2.4	1
224	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	1.4	1
225	Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11031-11031.	1.6	1
226	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2565-2565.	1.6	1
227	Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7566-7566.	1.6	1
228	A phase I multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2603-TPS2603.	1.6	1
229	A pilot study of levetiracetam as a sensitizer of temozolomide for newly diagnosed glioblastoma: A prospective, open-label, phase II study (KBTS-1601 study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2560-2560.	1.6	1
230	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3520-3520.	1.6	1
231	A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3562-3562.	1.4	1
232	Added Value of Contrast Leakage Information over the CBV Value of DSC Perfusion MRI to Differentiate between Pseudoprogression and True Progression after Concurrent Chemoradiotherapy in Glioblastoma Patients. <i>Investigative Magnetic Resonance Imaging</i> , 2022, 26, 10.	0.4	1
233	ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY). <i>Neuro-Oncology</i> , 2018, 20, vi23-vi23.	1.2	0
234	Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab069.	0.7	0

#	ARTICLE	IF	CITATIONS
235	Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14552-e14552.	1.6	0
236	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1624-1632.	2.6	0
237	Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2041-2041.	1.6	0
238	Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4544-4544.	1.6	0
239	Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5552-5552.	1.6	0
240	A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8521-8521.	1.6	0
241	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2098-2098.	1.6	0
242	Predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision cross-complementing-1 (ERCC1) in advanced urothelial carcinoma (UC) treated with first-line gemcitabine (G) and platinum (P)-based chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, e15614-e15614.	1.6	0
243	The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1590-1590.	1.6	0
244	Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18555-e18555.	1.6	0
245	Differentiation of True Recurrence from Delayed Radiation Therapy-related Changes in Primary Brain Tumors Using Diffusion-weighted Imaging, Dynamic Susceptibility Contrast Perfusion Imaging, and Susceptibility-weighted Imaging. <i>Journal of the Korean Society of Magnetic Resonance in Medicine</i> , 2014, 18, 120.	0.1	0
246	Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9543-9543.	1.6	0
247	Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17032-e17032.	1.6	0
248	Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6052-6052.	1.6	0
249	Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. <i>Journal of Clinical Oncology</i> , 2016, 34, 6078-6078.	1.6	0
250	Ipilimumab real-world efficacy and safety in Asian melanoma patients from the Korean Named-Patient Program cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21002-e21002.	1.6	0
251	Korean Cancer Patients's Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10067-10067.	1.6	0
252	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. <i>Blood</i> , 2016, 128, 4222-4222.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Diffuse large B-cell lymphoma in very elderly patients older than 80 years: A multicenter retrospective analysis of clinical characteristics, treatment patterns, and outcomeâ€”KCSG LY16-01.. Journal of Clinical Oncology, 2017, 35, e19031-e19031.	1.6	0
254	Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC). Blood, 2018, 132, 2917-2917.	1.4	0
255	Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. Korean Journal of Internal Medicine, 2019, 34, 894-901.	1.7	0
256	GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME. Neuro-Oncology, 2020, 22, iii328-iii329.	1.2	0
257	Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study. Blood, 2021, 138, 1397-1397.	1.4	0
258	288â€¦A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , .		0
259	Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma. Blood, 2020, 136, 32-34.	1.4	0
260	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2016, , .	1.7	0
261	Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC. Cancer Research, 2022, 82, 5477-5477.	0.9	0